Core Viewpoint - Myp Medical (301033.SZ) is planning to acquire at least 51% of Guangzhou Yijie Medical Technology Co., Ltd. (Yijie Medical), which is expected to constitute a major asset restructuring and related party transaction [1][2] Group 1: Acquisition Details - The acquisition will make Myp Medical the controlling shareholder of Yijie Medical, which specializes in stroke treatment products and has a presence in 100 cities across 20 countries [1][2] - Myp Medical has signed a letter of intent with major parties including Zexin Medical and Yichuangxiang, with the specific transaction plan to be disclosed within 10 trading days [2] Group 2: Company Performance - Myp Medical has shown continuous growth in performance, with Q1 2025 revenue and net profit increasing by 28.84% and 61.68% year-on-year, respectively [1][5] - The company reported a revenue increase from 539.3 million to 1.24 billion from 2017 to 2020, and from 1.54 billion to 2.78 billion from 2021 to 2024, with a compound annual growth rate of approximately 17% [5] Group 3: Financial Health - As of March 2025, Myp Medical had cash reserves of 38.37 million, total assets of 816 million, and total liabilities of 88.02 million, resulting in a debt-to-asset ratio of 10.79% [3] - The company has established strong relationships with nearly 1,000 distributors and its products are available in almost 2,000 hospitals in China [4] Group 4: Market Performance - Myp Medical's stock price has seen significant growth, rising from a low of 21.97 yuan per share in February 2024 to 64.13 yuan per share as of May 21, 2024, marking an increase of nearly 200% [6]

Group 1 - Qingmu Technology plans to reduce its shareholding by up to 3%, amounting to no more than 2.776 million shares [1] - Newcap received a decision from the police to revoke the case against its actual controller, who was previously detained for insider trading [2] - Rhine Biotech's directors and executives plan to collectively reduce their holdings by up to 0.14%, totaling no more than 1.0185 million shares [3] Group 2 - Puli Tui's stock and convertible bonds will be delisted on May 22, 2025 [5] - *ST Nong Shang will have its delisting risk warning lifted and will resume trading on May 23, 2025 [7] - State Grid Information Communication plans to acquire 100% equity of Yili Technology for approximately 1.853 billion yuan [9] Group 3 - Kelun Pharmaceutical's subsidiary received drug registration approval for a new injectable product, which is the first of its kind in China [10] - Aishida plans to acquire 7% equity of its subsidiary Zhejiang Qianjiang Robot Co., Ltd. for 13.09 million yuan [11] - Hongming Co. is planning to acquire 83% equity of Shenzhen Chisu Automation Equipment Co., Ltd. for approximately 151 million yuan [12] Group 4 - JuJiao Co. plans to reduce its shareholding by up to 2.6%, totaling no more than 2.093 million shares [14] - AVIC Financial's stock will be delisted on May 27, 2025 [16] - Jingwang Electronics' major shareholders plan to reduce their holdings by up to 2.99% [17] Group 5 - Huaren Health intends to acquire stakes in three pharmaceutical chain companies for a total of 327 million yuan [18] - Huanrui Century's original shareholders are required to compensate for unfulfilled performance commitments with 116 million shares [20] - Tefa Service's shareholders plan to reduce their holdings by up to 3% [21] Group 6 - Maipu Medical is planning to acquire at least 51% of Easy Medical's equity, which will constitute a major asset restructuring [22] - *ST Jinshi will have its delisting risk warning lifted and its stock will resume trading on May 23, 2025 [22] - Guoke Micro is planning a major asset restructuring and will suspend trading [23] Group 7 - Defu Technology intends to acquire 100% equity of an overseas electronic circuit copper foil company [24] - Xince Standard's shareholder plans to reduce its holdings by up to 1% [25] - Xiouqiang Co. plans to reduce its holdings by up to 3% [27]

Market Overview - The U.S. stock market experienced a significant decline, with all three major indices posting their largest drop in a month. The Dow Jones fell by 1.91%, the Nasdaq decreased by 1.41%, and the S&P 500 dropped by 1.61% [3] - Major technology stocks also saw declines, with Tesla and Apple each dropping over 2%, while Microsoft, Amazon, and Nvidia fell more than 1%. In contrast, Google saw an increase of nearly 3% [3] Economic Indicators - The yield on the 30-year Treasury bond rose to 5.09%, while the yield on the benchmark 10-year Treasury increased by 11.5 basis points to 4.59%. The 2-year Treasury yield also rose by 4.7 basis points to 4.01%, indicating a close relationship with interest rate expectations [3] Policy Measures - A joint announcement from several Chinese financial regulatory bodies outlined 23 measures to support financing for small and micro enterprises, focusing on increasing financing supply, reducing costs, and improving efficiency [4] - The Shanghai government released a special action plan to boost consumption, emphasizing the integration of advanced technologies like AI and big data into consumer sectors [5] Corporate Actions - Guokai Micro announced plans to acquire assets through a combination of stock issuance and cash payment, focusing on semiconductor wafer foundry and customized chip manufacturing, which is expected to constitute a major asset restructuring [7] - Vanke A signed a borrowing agreement with Shenzhen Metro Group for up to 4.2 billion yuan, using up to 6 billion yuan worth of stock as collateral [8] - Myp Medical is planning to acquire at least 51% of Easy Medical, which is expected to constitute a major asset restructuring [10] - Hongming Co. is planning to purchase 83% of Shenzhen Chisu Automation Equipment for an estimated 151 million yuan, which will also constitute a major asset restructuring [12]

停牌公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-026 停牌公告 时披露停牌期间筹划事项的主要工作、事项进展、对公司的影响以及 后续安排等事项，充分提示相关事项的风险和不确定性，并承诺自披 露相关公告之日起至少 1 个月内不再筹划重大资产重组事项。 广州迈普再生医学科技股份有限公司 关于筹划发行股份及支付现金购买资产 并募集配套资金暨关联交易事项的停牌公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、停牌事由和工作安排 广州迈普再生医学科技股份有限公司（以下简称"公司"）正在 筹划发行股份购买资产及支付现金购买资产并募集配套资金事项，根 据初步研究和测算，本次交易预计构成重大资产重组，构成关联交易， 不构成重组上市。因有关事项尚存不确定性，为了维护投资者利益， 避免对公司证券交易造成重大影响，根据深圳证券交易所的相关规定， 经公司申请，公司证券（证券品种：A 股股票，证券简称：迈普医学， 证券代码：301033）自 2025 年 5 月 22 日开市起开始停牌。 公司预计在不超过 10 个交易日的时间内披露本次交易方案，即 在 ...

股东大会决议公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-025 广州迈普再生医学科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有否决或变更议案的情况发生。 2、本次股东大会不涉及变更前次股东大会决议的情形。 一、会议召开和出席情况 （一）会议召开情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日下午 14:30 以现场表决和网络投票相结合的方式召 开公司 2024 年年度股东大会。 1、会议召开时间：2025 年 5 月 16 日（星期五）下午 14:30 2、会议召开地点：广州市黄埔区崖鹰石路 3 号迈普医学大厦会 议室 3、会议召开方式：采取现场表决与网络投票相结合的方式。现 场会议召开时间：2025 年 5 月 16 日（星期五）。网络投票时间：通 过深圳证券交易所交易系统进行网络投票的时间为：2025 年 5 月 16 股东大会决议公告 日上午 9:15-9:25，9:30-11:30 和下午 13:0 ...

北京市中伦（广州）律师事务所 关于广州迈普再生医学科技股份有限公司 北京市中伦（广州）律师事务所 关于广州迈普再生医学科技股份有限公司 2024 年年度股东大会的 法律意见书 二〇二五年五月 法律意见书 致：广州迈普再生医学科技股份有限公司 北京市中伦（广州）律师事务所（以下简称"本所"）接受广州迈普再生医 学科技股份有限公司（以下简称"公司"）委托，指派孙巧芬律师和曾思律师（以 下简称"本所律师"）对公司 2024 年年度股东大会（以下简称"本次股东大会"） 的合法性进行见证并出具法律意见。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"）、《证 券法》等现行有效的法律、法规、规范性文件以及《广州迈普再生医学科技股份 有限公司章程》（以下简称"《公司章程》"）、《广州迈普再生医学科技股份有限公 司股东大会议事规则》（以下简称"《股东大会议事规则》"）的规定而出具。 2024 年年度股东大会的 - 1 - 法律意见书 本所及本所律师依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《律师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规 则（试行）》等规定及本法律意见书 ...

Group 1: Company Overview - Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. is the only domestic enterprise in the neurosurgery field that simultaneously possesses artificial dura (spinal) membrane patches, craniofacial repair and fixation systems, absorbable regenerated oxidized cellulose, and dura mater medical glue [3] - The company has entered the international medical device market since 2011, covering over 100 countries and regions, with nearly 1.3 million products sold [3] Group 2: Financial Performance - In 2024, the domestic operating revenue reached ¥221,750,385.17, accounting for 79.64%, with a year-on-year growth of 22.63% [3] - The overseas operating revenue was ¥56,691,742.22, accounting for 20.36%, with a year-on-year growth of 13.28% [3] - The total revenue growth for 2024 was 20.61%, driven primarily by the artificial dura (spinal) membrane patches, which generated ¥155,593,757.71, accounting for 55.88% of total revenue, with an 11.46% increase [6] Group 3: Product Advantages - The absorbable dura (spinal) membrane patch "Rui Mo®" is the only product in China developed using bio-additive manufacturing technology combined with synthetic materials, offering a unique three-dimensional biomimetic porous micro-fiber structure [5] - The materials used are biodegradable and have good biocompatibility, providing higher biological safety compared to animal-derived materials [6] - The dura (spinal) membrane products generated sales revenue of ¥155,593,757.71, with an 11.46% increase year-on-year [6] Group 4: Future Development Strategy - The company emphasizes value management and aims to enhance core competitiveness while expanding into other surgical fields [4] - Plans to develop hemostatic and medical glue product lines, continuously launching new products to meet clinical needs [7] - The craniofacial repair products achieved sales revenue of ¥79,896,317.05, with a 31.05% increase year-on-year [10]

Industry Overview - Regenerative medicine (RM) utilizes biological and engineering theories to promote self-repair and regeneration of the body, or to construct new tissues and organs for repairing, regenerating, and replacing damaged tissues and organs [1][4] - The global regenerative medicine market is expanding, with the market size projected to grow from $20.04 billion in 2021 to $35.82 billion in 2024 [1][12] Market Status - Regenerative medicine is considered the "third medical revolution" following drug and surgical treatments, becoming a core component of life science strategies globally [6][12] - The industry includes upstream raw materials and equipment supply, midstream product R&D and production, and downstream application through medical institutions and aesthetic organizations [4][12] Policy and Regulatory Environment - Various countries have implemented policies to promote the development of regenerative medicine, such as the U.S. "21st Century Cures Act" and the EU's regulations on biotechnology [7][9] - In China, policies have been established to support the clinical application of regenerative medicine technologies, including the management of stem cell therapies and the promotion of innovative medical technologies [9][23] Market Competition - The regenerative medicine sector has attracted numerous companies, with major players including Johnson & Johnson, Bard, Geistlich, and domestic firms like Zhenghai Biological, Guanhou Biological, and Maipu Medical [16][18] - The market is characterized by a diverse range of products and applications, with companies focusing on specific therapeutic areas such as cancer treatment, tissue repair, and organ transplantation [18][20] Development Trends - The industry is witnessing technological integration and innovation, with advancements in 3D bioprinting, gene editing, and artificial intelligence enhancing treatment efficacy [22][24] - The dual drive of policy support and capital investment is accelerating the commercialization of regenerative medicine, with increasing coverage of medical insurance for regenerative products [23][24]

年度持续督导跟踪报告 华泰联合证券有限责任公司关于 广州迈普再生医学科技股份有限公司 2024 年度持续督导跟踪报告 | 保荐人名称：华泰联合证券有限责任公司 | 被保荐公司简称：迈普医学 | | --- | --- | | 保荐代表人姓名：胡轶聪 | 联系电话：0755-82492010 | | 保荐代表人姓名：张冠峰 | 联系电话：0755-82492010 | 一、保荐工作概述 | 项 目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2、督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限 | | | 于防止关联方占用公司资源的制度、募集资金管理 | 是 | | 制度、内控制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 0 次，募集资金专户已于 2021 年注销 | | （2）公司募 ...

华泰联合证券有限责任公司 关于广州迈普再生医学科技股份有限公司 2024年度内部控制自我评价报告的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合"）作为广州迈普再生医学科 技股份有限公司（以下简称"迈普医学"、"公司"或"发行人"）首次公开发行股 票并在创业板上市的保荐人，根据《证券发行上市保荐业务管理办法》、《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等文件的要求， 华泰联合对迈普医学 2024 年度内部控制制度等相关事项进行核查，并发表独立意见如 下： 一、内部控制评价范围 公司按照风险导向原则确定纳入评价范围的主要单位、业务和事项以及高风险领 域。 内部控制自我评价报告的核查意见 纳入评价范围的主要单位包括公司及子公司，及其各事业部和职能部门，纳入评 价范围单位资产总额占公司合并财务报表资产总额的 100%，营业收入合计占公司合并 财务报表营业收入总额的 100%。 纳入评价范围的主要业务和事项包括；组织结构、内部审计、资金活动、募集资 金使用和管理、发展战略、人力资源、企业文化建设等；重点关注的高风险领域主要 包括：风险管理机制、采购业务、销售业务、固定资产内部 ...